You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed, refractory patient

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Mar 6, 2023

Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

Recruiting
  • Non-Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +3 more
Apr 4, 2023

Multiple Myeloma, Refractory Multiple Myeloma Trial in Houston (Digital Health Coaching Program, Fitbit)

Recruiting
  • Multiple Myeloma
  • Refractory Multiple Myeloma
  • Digital Health Coaching Program
  • Fitbit
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jun 17, 2022

Multiple Myeloma, Relapsed Hematologic Malignancy Trial in Seattle (Digital Health Coaching Program, Fitbit)

Recruiting
  • Multiple Myeloma
  • Relapsed Hematologic Malignancy
  • Digital Health Coaching Program
  • Fitbit
  • Seattle, Washington
    University of Washington
Jul 13, 2023

Usability of Cellworks Singula™ and Cellworks Ventura™ Reports

Recruiting
  • Cancer
  • +2 more
  • Cellworks Report
  • Sioux Falls, South Dakota
    Avera Cancer Institute
Jan 20, 2023

Advanced Solid Tumor, Relapsed AML, Refractory AML Trial in Hong Kong (NEI-01)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • Hong Kong, Hong Kong
    The University of Hong Kong Phase I Clinical Trials Centre
May 6, 2022

Multiple Myeloma Trial in Winston-Salem (TNB-383B)

No longer available
  • Multiple Myeloma
  • Winston-Salem, North Carolina
    Wake Forest
Sep 16, 2021

B-cell Non-Hodgkin's Lymphoma Trial (Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
  • (no location specified)
Oct 12, 2021

Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,

Active, not recruiting
  • Relapsed Angioimmunoblastic T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-cell Lymphoma
  • Oral azacitidine
  • +3 more
  • Graz, Austria
  • +33 more
Aug 24, 2022

Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance

Active, not recruiting
  • Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
    • Aichi, Japan
    • +48 more
    Dec 7, 2022

    Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))

    Not yet recruiting
    • Refractory Cancer
    • Relapsed Cancer
    • Drug Sensitivity Test (DST)
    • Weston, Florida
      Lerner College of Medicine: Cleveland Clinic Florida
    Sep 1, 2023

    NSCLC, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Tumor of Lung Trial in United States (sapanisertib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +3 more
    • Davis, California
    • +13 more
    Nov 7, 2022

    Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

    Recruiting
    • Hepatocellular Carcinoma
    • +3 more
    • NKG2D-based CAR T-cells
    • Jiujiang, Jiangxi, China
      Xunyang Changchun Shihua Hospital
    Nov 20, 2021

    Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

    Not yet recruiting
    • Relapsed and/or Refractory Multiple Myeloma
    • Köln, Germany
      Local Institution - 0017
    Dec 4, 2023

    Multiple Myeloma Trial in Nagoya-shi, Shibukawa-shi, Osaka-shi (Elotuzumab, Lenalidomide, Dexamethasone)

    No longer available
    • Multiple Myeloma
    • Nagoya-shi, Aichi, Japan
    • +3 more
    Nov 17, 2021

    Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

    Recruiting
    • Relapsed or Refractory CD19+ B-cell Lymphoma
    • +2 more
    • TBI-2001
    • +2 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jul 26, 2023

    Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Relmacabtagene Autoleucel Injection
    • (no location specified)
    Apr 13, 2023

    Precision Medicine for Every Child With Cancer

    Recruiting
    • Childhood Cancer
    • +5 more
    • Whole Genome Sequencing
    • +6 more
    • Adelaide, Australia
    • +8 more
    Jan 24, 2023

    Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

    Recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Beijing, Beijing, China
      Han wei dong
    Jun 14, 2023

    Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

    Not yet recruiting
    • Relapsed and Refractory Multiple Myeloma
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Sep 15, 2023

    Quality of Life in Adult Chronic Lymphocytic Leukemia Receiving

    Recruiting
    • Chronic Lymphocytic Leukemia
      • Granada, Spain
      • +4 more
      Nov 8, 2023

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Oct 30, 2023

      Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome, Relapsed/Refractory Acute Myeloid Leukemia Trial (Magrolimab)

      Available
      • Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
      • Relapsed/Refractory Acute Myeloid Leukemia
      • Magrolimab
      • (no location specified)
      Jan 18, 2023

      Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)

      Recruiting
      • Refractory Solid Tumors
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 22, 2023

      Relapsed or Refractory Lymphomas, Advanced Solid Tumor Trial in Los Alamitos (LP-284)

      Not yet recruiting
      • Relapsed or Refractory Lymphomas
      • Advanced Solid Tumor
      • Los Alamitos, California
        Cancer and Blood Specialty Clinic
      Nov 9, 2023